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Abstract
Increasing evidence suggests there is a relationship between cognitive impairment and metabolic dysfunction.
Diabetes is a chronic disease, and metabolic factors affecting brain metabolisms, such as serum glucose, insulin, and
glucagon, are altered according to disease progression. In our previous study, we applied hyperpolarized [1-13C]
pyruvate magnetic resonance spectroscopy in prediabetic mice after feeding them a 60% high-fat diet (HFD) for
6 months. Ultimately, we detected significantly increased [1-13C]lactate conversion in the whole brain and an
almost five-fold increased [1-13C]lactate/pyruvate ratio in the hippocampal region. In the present study, we induced
diabetes in mice by injecting streptozotocin and feeding them an HFD for 6 months. Unlike in prediabetic
mice, [1-13C]lactate conversion in the diabetic mice did not differ from that in the control group, but [1-13C]lactate/total
13C ratio showed an almost 1.4-fold increase in the hippocampal region. We measured the amount of the lactate and
mRNA levels of glucose transporters from isolated hippocampus and cortex samples. In the hippocampus, significantly
decreased GLUT1 mRNA levels and increased lactate were detected, suggesting an inconsistency between glucose and
pyruvate metabolism. Pyruvate can be produced from oxaloacetate as well as glucose. We investigated ATP
citrate lyase (ACLY) because it cleaves citrate into oxaloacetate and acetyl CoA. Phosphorylated ACLY (Ser455),
the active form, was increased in both hippocampus and cortex samples of mice injected with streptozotocin
and fed an HFD. Also, phosphorylated ACLY/total ACLY showed a positive correlation with lactate amount in
the hippocampus. Our results suggest that the brain has different responses to diabetic progression, but, in
the hippocampus, maintains metabolic alteration toward increasing lactate production from the prediabetic to
the diabetic stage. We suggest that ACLY-mediated pyruvate be used to support lactate levels in the hippocampus in
cases of limited glucose availability.
Keywords: Brain metabolism, Hyperpolarized 13C, Pyruvate metabolism, Diabetes, ATP citrate lyase, Magnetic
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Introduction
Diabetes has been recognized as a risk factor for Alzhei-
mer’s disease. According to epidemiological research,
patients with diabetes demonstrate dementia at a rate
that is two to three times higher than that of those with-
out diabetes [1, 2]. Also, neuroimaging has revealed the
appearance of cortical atrophy and a decrease in hippo-
campal volume in type 2 diabetes that is similar to that
seen in the brains of Alzheimer’s disease patients [3, 4].
Furthermore, results obtained in animal studies show
that diabetic animal models progressed to cognitive
decline regardless of the method to induce diabetes,
such as genetic factors (db/db mice), beta cell damage by
streptozotocin, or feeding with a high-fat diet (HFD) [5–
7]. Even though the literature suggests a clear
relationship between diabetes and Alzheimer’s disease,
how exactly diabetes induces cognitive decline is not yet
clearly understood. As insulin resistance is the major
hallmark of type 2 diabetes, impaired insulin action in
the brain might engender cognitive impairment.
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Actually, the cerebrospinal fluid/serum insulin ratio was
reported to be reduced in both type 2 diabetes and
Alzheimer’s disease [8, 9], and intranasal-delivered insu-
lin improved cognitive function in a patient with dia-
betes without changing serum glucose level [10, 11],
supporting the suggestion that insulin resistance induced
cognitive decline. However, there are conflicting results
that mice having impaired insulin receptors developed
insulin resistance but did not experience accelerated
cognitive decline in an Alzheimer’s disease model [12].
In addition, elevated serum glucose levels in people
without diabetes were associated with the development
of dementia [13], while acute hyperglycemia increased
amyloid beta levels in the hippocampal interstitial fluid
in an Alzheimer’s disease model [14], leading to the
implication that hyperglycemia could induce cognitive
impairment as well. Given the fact that diabetes is a
chronic disease and metabolic factors such as serum
glucose, insulin, and glucagon are altered by disease
progression [15, 16], new information about how the
brain responds to disease progression could provide
insight into the development of Alzheimer’s disease in
patients with diabetes.
Hyperpolarized 13C magnetic resonance spectroscopy
(MRS) can detect in vivo metabolism with 10,000-fold
increased sensitivity and can trace metabolic fate by
injecting 13C metabolic substrate [17, 18]. Pyruvate is
the important metabolic product of glycolysis and is
located between cytoplasmic metabolism by converting
lactate and mitochondrial metabolism by converting
acetyl CoA [19]. In a previous study, we reported meta-
bolic changes achieved using hyperpolarized [1-13C]
pyruvate MRS in the brain of prediabetic mice by feed-
ing them an HFD for 6 months. These mice experienced
weight gain with hyperglycemia, but there was no differ-
ence in glucose tolerance test outcomes. They showed
significantly increased hyperpolarized lactate conversion
in the whole brain, and the medial temporal lobe con-
taining the hippocampus was the prominent region for
this metabolic alteration [20], suggesting that increased
lactate production is associated with cognitive decline.
In this study, we investigated whether the metabolic
alterations seen in prediabetes are maintained or chan-
ged according to disease progression. To induce beta cell
damage, mice were injected with 100 mg/kg of strepto-
zotocin and fed a 60% HFD for 6 months, then subjected
to a hyperpolarized [1-13C] pyruvate MRS study in the
brain.
Materials and methods
Animal procedures
Seven weeks old male ICR mice were purchased from
Japan SLC, a branch of Charles River Laboratories
(Shizuoka, Japan). The mice were fed either a normal
diet (ND; 5053, 13.1 kcal % fat; PicoLab, Tokyo, Japan)
or an HFD (fat 54.3% kcal of lard, 5.6% kcal of soybean
oil; D12492; Research Diets Inc., New Brunswick, NJ,
USA) for 24 weeks. All animal procedures were carried
out according to a protocol approved by the Inter-
national Animal Care and Use Committee (IACUC) of
the Yonsei University Animal Research Center (YLARC;
permission no. 2017–0018) following the National Insti-
tutes of Health guidelines. All animals were maintained
in a specific pathogen-free facility of the YLARC with a
well-controlled temperature (23 °C) and light cycle (12 h
of light and 12 h of dark) and easy access to water and
food.
To induce type 2 diabetes, mice that were fed an HFD
(60% kcal fat) for 1 month received a single injection of
a low dose of streptozotocin (100 mg/kg/ip) dissolved in
citrate buffer (pH.4.4) and then were maintained con-
tinuously on an HFD diet [21].
Intraperitoneal glucose tolerance test (IPGTT)
The intraperitoneal glucose tolerance test was performed
at 12 weeks after a high-fat diet. Mice were fasted over-
night and injected with glucose (1 g/kg/ip, dissolved in
saline) in the morning. Blood sampels were taken from
the tail vein and blood glucose levels were measured
using a glucometer at 0, 30, 60, and 120 min after the
bolus [10].
Hyperpolarized 13C MR spectroscopy
Mice were fasted for 4–5 h before hyperpolarized 13C
MR spectroscopy. A total of 26.7 mg of [1-13C] pyruvic
acid (Cambridge Isotope, Tewksbury, MA, USA) was
mixed with 15mM of trityl radical OX-063 (Oxford
Instruments, Oxford, UK) and 0.75 mM of gadoterate
meglumine (Dotarem®; Guerbet, Villepinte, France). This
[1-13C] pyruvic acid sample was hyperpolarized using a
dynamic nuclear polarization system (HyperSense®;
Oxford Instruments, Oxford, UK) and dissolved with
3.8 mL of Tris/EDTA-NaOH buffer, resulting in 79mM
of pyruvate (pH: 7.5) with a polarized level of approxi-
mately 20%. We drew 350 μL of hyperpolarized [1-13C]
pyruvate into a syringe for in vivo MRS. In-vivo experi-
ments were performed on a 9.4 T Bruker BioSpec 94/20
small animal imaging MRI scanner (Bruker Biospin MRI
GmbH, Ettlingen, Germany) equipped with a 13C
receive-only mouse brain surface coil. T2 weighted 1H
images were acquired for 7 coronal slices with a thick-
ness of 3.5 mm. Afterwards, hyperpolarized 13C free
induction decay (FID) chemical shift image was obtained
using centric-ordered phase encoding with a flip angle
of 10°, field of view of 18 × 24mm2, matrix size of 18 ×
24, slice thickness of 3.5 mm, spectral bandwidth of
6510.4 Hz, spectral points of 512, and spectral resolution
of 12.7 Hz. Imaging acquisition started 18 s after the
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start of the intravenous injection of pyruvate, and the
total acquisition time was 35 s. Each FID signal was
zero-filled with three times of spectral points and filtered
with exponential apodization function. In voxel-based
analysis, we calculated the hyperpolarized [1-13C]lactate/
total 13C ratio to compensate for the inhomogeneous
substrate perfusion and coil sensitivity [22]. All data
were processed using MATLAB-based analysis (R2017a;
MathWorks, Natick, MA, USA).
Tissue sample preparation
After finishing hyperpolarized 13C MR spectroscopy, the
mice were maintained under the same experimental con-
dition for almost 3–6 days and then sacrificed via CO2
inhalation after fasting for nearly 4 h. Brains were col-
lected and placed in saline, and the hippocampus and
cortex were carefully isolated. Tissues were frozen in
liquid nitrogen and stored at − 80 °C. For in vitro study,
tissues were homogenized in phosphate-buffered saline
(PBS) without calcium and magnesium and divided into
three vials for RT-PCR, western blot, and lactate meas-
urement, respectively.
Assessment of lactate level
Lactate levels were measured using the lactate colori-
metric assay kit (Biovision, San Francisco, CA, USA).
Tissue samples were lysed using an NP-40 buffer. After
measuring BCA-based protein concentrations, 40 μg of
lysate was used according to the manufacturer’s instruc-
tions to detect lactate concentration. The absorbance
was measured at 450 nm.
Western blot
Protein was isolated using ice-chilled RIPA lysis and
extract buffer (Thermo Fisher Scientific, Waltham, MA,
USA) containing phosphatase inhibitors (5 mM of β-
glycerophosphoric acid, 10 mM of NaF, and 1mM of
Na3VO4), 1 mM of PMSF, and protease inhibitor cock-
tail (Sigma Aldrich, St. Louis, MO, USA). Homogenate
containing 15 μg of protein was subjected to 10% SDS-
PAGE under reducing conditions. The proteins were
transferred to PVDF membranes in transfer buffer and
then separated at 400 mA for 2 hours at 4 °C. The
Western blots were subsequently incubated for 2 hours
with 5% skim milk at room temperature and then incu-
bated overnight with a 1:1000 dilution of anti-LDHA
(NBP1–48336; Novus Biologicals, Centennial, CO,
USA), anti-LDHB (AB85319; Abcam, Cambridge, UK),
phospho–ATP–citrate lyase (Ser455) (4331; Cell Signal-
ing Technology, Danvers, MA, USA), ATP-Citrate lyase
(4332, Cell Signaling Technology, MA, USA) anti-β-
actin (sc-47,778; Santa Cruz Biotechnology, Dallas, TX,
USA), Then, the blots were washed twice with Tween
20/Tris-buffered saline (TTBS) and incubated with a 1:
3000 dilution of horseradish peroxidase-conjugated sec-
ondary antibody for 2 hours at room temperature. After
washing three times with TTBS, blots were developed
using WEST-SAVE Up luminol-based ECL reagent
(ABfrontier, Seoul, Korea). The membranes were ana-
lyzed using the ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
RT-PCR
Trizol reagent (Gibco Laboratories, Gaithersburg, MD,
USA) was used to extract total RNA by following the
manufacturer’s instructions. TOYOBO ReverTra Ace®
qPCR RT Master Mix (Toyobo, Osaka, Japan) was used
to obtain complementary DNA using 800 ng of total
RNA. PCR reaction was performed using ready-2x-Go
Taq (NanoHelex, Daejeon, Korea) in the C1000 Touch™
Thermal Cycler (Bio-Rad Laboratories, Hercules, CA,
USA), following the manufacturer’s guidelines. PCR
products were run on a 1.5% agarose gel in TAE buffer
and visualized using the MiniBIS Bioimaging system
(Neve Tamin, Israel). Gene expression levels were ana-
lyzed using the ImageJ software. The primers used were
as seen in Table 1.
Statistical analysis
Statistical analyses were performed to compare the two
groups: mice on a normal diet vs. streptozotocin-
injected mice on an HFD using the Student’s t-test.
Pearson’s correlation coefficient is used to determine the
linear relationship between pACLY/ACLY ratio and lac-
tate level in the brain tissues. All results were expressed
as means ± standard error of the mean (SEM), and p <
0.05 was considered to be statistically significant. Statis-
tical analysis was performed using statistical software
(PRISM version 6.0; GraphPad Software, San Diego, CA,
USA).
Table 1 PCR primers
Gene Cycle size
Glut1 Forward GGGTCTTAAGTGCGTCAGGG 30 312
NM_011400.3 Reverse AGAGAGACCAAAGCGTGGTG
Glut2 Forward ACCGGGATGATTGGCATGTT 35 288
NM_031197.2 Reverse GAACACGTAAGGCCCAAGGA
Glut3 Forward TGTGGTAAAAAGCAGGAGGGG 35 251
NM_011401.4 Reverse TGTTCCTCGGGTCCTACAGA
Glut4 Forward TCACTAGATCCCGGAGAGCC 35 235
NM_001359114.1 Reverse GGGTTCCCCATCCTTACGTC
GAPDH Forward CCCTTAAGAGGGATGCTGCC 30 124
NM_001289726.1 Reverse TACGGCCAAATCCGTTCACA
β-actin Forward GATTACTGCTCTGGCTCCTAG 30 147
NM_007393.5 Reverse ACTCATCGTACTCCTGCTTG
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Results
Mice injected with streptozotocin and fed an HFD had
increased fast serum glucose and showed glucose
intolerance
Streptozotocin-injected mice fed an HFD (HFD + STZ)
showed significant weight gain (Fig. 1b) and increased
fasting serum glucose levels (Fig. 1c). Also, they showed
significantly impaired glucose tolerance test findings
(Figs. 1d-e).
Higher hyperpolarized [1-13C]lactate/total 13C ratio is
visualized in the region containing the hippocampus in
mice injected with streptozotocin and fed an HFD
To investigate the brain response to the metabolic
change provoked by diabetes, we performed hyperpolar-
ized 13C MR chemical shift imaging in the brain. The
hyperpolarized [1-13C] pyruvate signal revealed a down-
ward trend, suggesting decreased cerebral perfusion.
However, [1-13C]lactate production was still maintained
and a higher [1-13C] lactate/total 13C ratio was visualized
in the brains of mice injected with streptozotocin and
fed an HFD (Fig. 2a). The [1-13C]lactate/total 13C ratio
was significantly increased in the region containing the
hippocampus in the brains of mice injected with strepto-
zotocin and fed an HFD (Fig. 2b).
Lactate level increased in the hippocampus of mice
injected with streptozotocin and fed an HFD
Since the signal intensity of hyperpolarized [1-13C]
lactate reflects the amount of lactate pooled in tissue
[23], we measured lactate level in the hippocampus
and cortex to validate our hyperpolarized [1-13C]
pyruvate imaging study. We found that lactate level
was significantly increased in the hippocampus
(Fig. 3a) but it was not significantly increased in the
cortex (Fig. 3e) of mice injected with streptozotocin
and fed an HFD. However, there was no difference in
lactate dehydrogenase A (LDHA) or LDHB protein
levels in both the hippocampus (Figs. 3b-d) and cor-
tex (Figs. 3f-h).
Gene expression level of glucose transporter 1 was
decreased in the hippocampus of mice injected with
streptozotocin and fed an HFD
Since lactate is one of the major products of glucose
metabolism created via glycolysis in the cytoplasm, we
Fig. 1 Weight gain, hyperglycemia, and impaired glucose tolerance were observed in the streptozotocin-injected mice fed an HFD (HFD + STZ). a
Experimental schedule. b Body weight was measured every 4 weeks for each diet group. c Four-hour fasting for serum glucose level was
measured at 10 weeks and 22 weeks. d Changes in the glucose level during the intraperitoneal glucose tolerance test (GTT). e The area under the
curve (ACU) of the glucose level was calculated during the IPGTT. STZ; streptozotocin. IPGTT; intraperitoneal glucose tolerance test. Values are
expressed as means ± SEMs (n = 5 for both groups). * p < 0.05, ** p < 0.01, *** p < 0.001
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investigated the expression level of glucose transporters
(GLUT) in both the hippocampus and cortex to eluci-
date whether increased lactate production was the re-
sult of increased glucose uptake in the mice injected
with streptozotocin and fed an HFD. GLUT1 expres-
sion was decreased in the hippocampus of the mice fed
an HFD (Fig. 4a and b) but no difference was seen in
the cortex (Fig. 4d and e). On the other hand, the
GLUT3 expression level was similar in both groups
(Fig. 4a, c, d, and f). Separately, GLUT2 and 4 were
hardly detected in both the hippocampus and cortex
(data not shown).
Fig. 2 Chemical shift imaging of hyperpolarized 13C MRS. a Color maps overlaid on the 1H images represent [1-13C] pyruvate and [1-13C] lactate
peak intensities, and [1-13C] lactate/total 13C intensity ratios. The images were acquired for 35 s from 18 s after intravenous injection of 79 mM of
hyperpolarized 13C-pyruvate in the coronal plane with a 3.5-mm slice thickness and 1 × 1mm2 in-plain resolution. White boxes indicate voxels
containing hippocampus. b [1-13C] lactate/total 13C intensity ratios calculated each voxel of the region containing the whole brain, striatum,
hippocampus, and midbrain. Values are expressed as mean ± SEMs (n = 4–5 for both groups). * p < 0.05
Fig. 3 Increased lactate level detected in the hippocampus of streptozotocin-injected mice fed an HFD (HFD + STZ). a The amount of lactate in
40 μg of a lysate measured in the hippocampus. b LDHA and LDHB protein levels were measured by western blot assay. c LDHA and d LDHB
protein levels were quantified by the ratio to β-actin in the hippocampus. e Amount of lactate in 40 μg of a lysate of the cortex. f Cropped
images of LDHA and LDHB in the cortex. g Quantified LDHA and h LDHB in the cortex by the ratio to β-actin. Values are expressed as means ±
SEMs (n = 5 for both groups). * p < 0.05
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Phosphorylated ATP citrate lyase (ACLY) increased in
mice injected streptozotocin and fed an HFD
Even though there are conflicting results regarding glu-
cose transporter expression level in the brain affected by
diabetes [24–26], the ability to import glucose into the
brain has been suggested to be decreased in a manner
similar to our results shown in Fig. 4a and b. Therefore,
we investigated the possible metabolic pathway to sup-
port pyruvate except for glycolysis. We focused on ATP
citrate lyase (ACLY) because it converts citrate into
acetyl CoA and oxaloacetate (OAA). From OAA, pyru-
vate can be produced via phosphoenolpyruvate carboxy-
kinase (PEPCK) and pyruvate kinase or via malate
dehydrogenase (MDH) and malic enzyme 1 (ME1)
(Fig. 5a). Since the phosphorylation of ACLY on Ser455
has been reported to enhance the catalytic activity [27,
28], we measured it in both the hippocampus and cor-
tex. Phosphorylated ACLY on Ser455 increased in both
the hippocampus (Fig. 4b) and cortex (Fig. 4c), but the
total ACLY level was not significantly increased.
Lactate level correlated with phosphorylated ATP citrate
lyase in the hippocampus of mice fed an HFD
To investigate the possibility that ACLY-mediated pyru-
vate production supports lactate production, we calcu-
lated the Pearson’s correlation coefficient value between
the amounts of lactate and the phosphorylated ACLY
ser455 in both the hippocampus and cortex. As shown
in Fig. 6, the lactate level demonstrated a positive correl-
ation with pACLY levels in the hippocampus but not in
the cortex. This suggests that increased lactate in the
hippocampus of mice injected with streptozotocin and
fed an HFD may come from ACLY-mediated pyruvate
production in the face of limited glucose availability.
Discussion
In the present study, we extend our previous work by
performing hyperpolarized 13C pyruvate in vivo imaging
in diabetic mice, which have considerably impaired glu-
cose tolerance, to compare brain response to that of
control mice. Our results indicate that a significantly
increased hyperpolarized lactate/total 13C ratio can be
detected in the hippocampus, even though the GLUT1
mRNA level was decreased.
With our previous finding in the brains of prediabetic
mice, the hyperpolarized 13C lactate flux significantly
increased approximately 4.5-fold and 5-fold in the whole
brain and the region containing the hippocampus, re-
spectively [20]. However, from this study in diabetic
mice, the hyperpolarized 13C lactate flux did not show
any difference between diabetic mice and controls in the
whole brain, and a significant increase of about 1.4-fold
in the region containing the hippocampus was observed
in diabetic mice. Therefore our results support that
Fig. 4 GLUT1 mRNA level was decreased in the hippocampus of the streptozotocin-injected mice fed an HFD (HFD + STZ). a Representative RT-
PCR product bands of GLUT1, GLUT3, and GAPDH mRNA expression in the hippocampus. b GLUT1 and c GLUT3 gene expression levels were
quantified by the ratio to GAPDH in the hippocampus. d Representative RT-PCR product bands of GLUT1, GLUT3, and GAPDH mRNA expression
in the cortex. e Quantified GLUT1 and f GLUT3 in the cortex by the ratio to β-actin. Values are expressed as means ± SEMs (n = 5 for both
groups). * p < 0.05
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different brain regions respond to metabolic stress ac-
cording to disease progression, and lactate production is
activated in the region containing the hippocampus
during prediabetic to diabetic progression, although the
degree of increase is different.
Metabolic imaging studies suggest decreased 18F-FDG
uptake occurs in Alzheimer’s disease [29], and this hypo-
metabolism can be observed prior to the symptoms [30,
31]. Decreased FDG-PET uptake presents in both
patients with prediabetes and type 2 diabetes [32, 33],
suggesting that reduced glucose metabolism in the brain
induces cognitive impairment. Also, impaired insulin sig-
naling pathways [21, 34, 35] and reduced glucose trans-
porter levels are seen in Alzheimer’s disease [36, 37] and
could support that a hypoglucose metabolism leads to
induce cognitive decline. However, our results suggest
the inconsistency of glucose and pyruvate metabolism in
the hippocampus of diabetic mice, as the level of GLUT1
expression was decreased and that of lactate was
increased.
From the classical point of view, glucose is the primary
energy source to be used in both neurons and astrocytes,
and lactate is considered a by-product. Recently, the
concept of the astrocyte–neuron lactate shuttle hypoth-
esis has been supported with a number of research
papers. This hypothesis suggests that astrocytes uptake
glucose, produce lactate via glycolysis, and then release
it to extracellular spaces. Meanwhile, neurons uptake
lactate and use it as an energy source to make ATP
using oxidative phosphorylation in the mitochondria
[38]. Because astrocytes have greater metabolic plasticity
than neurons, the astrocyte–neuron lactate shuttle
system makes it possible for neurons to maintain their
function in stress conditions such as diabetes or hypoxia
Fig. 6 Amount of lactate showed a positive correlation with phosphorylated ACLY in the hippocampus of streptozotocin-injected mice fed an
HFD (HFD + STZ). a Person’s correlation coefficient value calculated in the hippocampus and (b) in the cortex between the amount of lactate and
the pACLY/ACLY ratio
Fig. 5 Phosphorylated ACLY (Ser455) increased in both the hippocampus and cortex in the streptozotocin-injected mice fed an HFD (HFD + STZ).
a Expected metabolic pathway to supply pyruvate via ACLY. OAA; oxaloacetate, ME1; malic enzyme1, MDH; malate dehydrogenase, PEPCK;
phosphoenolpyruvate carboxykinase, PK; pyruvate kinase, ACLY; ATP citrate lyase. b Phosphorylated ACLY (Ser455) and total ACLY protein levels
were measured by western blot assay. Phosphorylated ACLY (Ser455) was quantified by the ratio of total ACLY; representative cropped images in
the hippocampus and c in the cortex are presented. Values are expressed as means ± SEMs (n = 5 for both groups). * p < 0.05., ** p < 0.01
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[38, 39]. Therefore, the inconsistency of glucose and
pyruvate metabolism in our results may reflect that as-
trocytes support lactate production in the case of limited
glucose availability to support neuronal function. We
suggest that ACLY supports lactate in the hippocampus
of diabetic mice. The expression pattern of ACLY in the
brain is interesting because the amount of ACLY level
decreases with age, yet a relatively high expression level
was detected in the hippocampus in adult mice [40],
suggesting ACLY plays a role in the hippocampus. In-
creased levels of citrate, acetyl CoA, and lactate in the
brain of streptozotocin-induced diabetic rats [41] may
support the role of ACLY to produce lactate in the brain
in diabetes because of ACLY cleaves citrate into acetyl
CoA and OAA.
In our result, the amount of lactate showed a positive
correlation with phosphorylated ACLY in the hippocam-
pus, but not in the cortex. Several factors regulate the
amount of lactate, including glycolysis, the activity of
pyruvate dehydrogenase, and NAD+/NADH redox state
[42, 43]. Therefore, the regional difference of those
factors may result in a different correlation between
phosphorylated ACLY and the amount of lactate level.
In this study, we showed altered brain metabolism to-
ward increased lactate level. However, it remains unclear
as to whether the increased amount of lactate in the
hippocampus induces cognitive decline or whether the
altered metabolic pathway to support lactate production
causes cognitive decline.
Increased ACLY activity in the brain of diabetes might
be related to lipid accumulation in the brain. Fatty acid
synthesis occurs in the cytoplasm by serial chain elong-
ation of acetyl CoA. Therefore, knowing the role of
ACLY in the cytoplasm and of supporting acetyl CoA is
essential [27, 28]. The importance of lipid metabolism in
cognitive decline is emphasized by the fact that lipid in-
clusion in glial cells is one of the pathologic hallmarks
reported by Dr. Alzheimer [44]. Also, aging, one of the
risk factors for Alzheimer’s disease, was reported to cor-
relate with increasing lipid accumulation in both aged
mice with Alzheimer’s disease and aged normal Balb/C
mice [45, 46].
The other supporting evidence that lipid accumulation
leads to a cognitive decline can be taken from the results
obtained in the people having apolipoprotein E (ApoE)
ε4 polymorphism. These individuals have a higher risk
of developing Alzheimer’s disease than do those with
ApoE ε3 polymorphism, the most common form. ApoE
isoforms have different affinities for transporting lipid,
and ApoE ε4 has been known to have a lesser degree of
efficacy in comparison with APOE ε3 [47, 48]. Also,
people having both diabetes and ApoE ε4 have more
than twice the risk of developing Alzheimer’s disease
than do those with ApoE ε4 alone [49]. Interestingly,
there was no difference in cognitive function in the nor-
mal diet–fed condition between genetic mice having
ApoE ε4 and ApoE ε3. However, mice having ApoE ε4
showed significantly impaired cognitive function com-
pared to mice having ApoE ε3 when fed an HFD [50].
This finding suggests the greater importance of lipid
accumulation than ApoE polymorphism in the develop-
ment of Alzheimer’s disease. Therefore lipid accumula-
tion in the brain by diabetes or metabolic stress may
boost the development of cognitive decline in people
having ApoE ε4. In this study, we proposed that ACLY
plays a potential role in producing lactate in the diabetic
state, and this metabolic adaptation may induce lipid
synthesis. However, further study is required to investi-
gate whether astrocyte promotes ACLY-mediated lactate
production in the face of limited glucose supply. Also,
we must further review whether ACLY activation stimu-
lates lipid accumulation in the brain of diabetic mice.
In this work, our hyperpolarized 13C pyruvate imaging
shows that different brain regions respond differently to
metabolic stress according to diabetes progression, but
significantly higher hyperpolarized 13C lactate flux visu-
alized in the hippocampus of diabetes. With the incon-
sistency of GLUT1 mRNA expression level and amount
of lactate in the hippocampus of diabetes, we suggest
that ACLY supplies lactate in the case of limited glucose
availability to support neuronal function. Lipid accumu-
lation in glial cells was one of the pathologic hallmarks
of Alzheimer’s disease, and the role of ACLY for fatty
acid synthesis is essential. Thus, our result would
provide a clue to investigate further the relationship
between lipid accumulation in the brain of diabetes and
Alzheimer’s disease progression.
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